From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1).

Using fragment-based screening of a focused fragment library, 2-aminoquinoline 1 was identified as an initial hit for BACE1. Further SAR development was supported by X-ray structures of BACE1 cocrystallized with various ligands and molecular modeling studies to expedite the discovery of potent compounds. These strategies enabled us to integrate the C-3 side chain on 2-aminoquinoline 1 extending deep into the P2' binding pocket of BACE1 and enhancing the ligand's potency. We were able to improve the BACE1 potency to subnanomolar range, over 10(6)-fold more potent than the initial hit (900 μM). Further elaboration of the physical properties of the lead compounds to those more consistent with good blood-brain barrier permeability led to inhibitors with greatly improved cellular activity and permeability. Compound 59 showed an IC(50) value of 11 nM on BACE1 and cellular activity of 80 nM. This compound was advanced into rat pharmacokinetic and pharmacodynamic studies and demonstrated significant reduction of Aβ levels in cerebrospinal fluid (CSF).

[1]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[2]  P. Borst,et al.  Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. , 1995, The Journal of clinical investigation.

[3]  R. Kim,et al.  Development and characterization of LLC-PK1 cells containing Sprague-Dawley rat Abcb1a (Mdr1a): comparison of rat P-glycoprotein transport to human and mouse. , 2006, Journal of pharmacological and toxicological methods.

[4]  Jian Sun,et al.  Fragment-based discovery of nonpeptidic BACE-1 inhibitors using tethering. , 2009, Biochemistry.

[5]  B. Strooper,et al.  The secretases: enzymes with therapeutic potential in Alzheimer disease , 2010, Nature Reviews Neurology.

[6]  N. Kumaragurubaran,et al.  Recent developments of structure based beta-secretase inhibitors for Alzheimer's disease. , 2005, Current topics in medicinal chemistry.

[7]  Rutger H A Folmer,et al.  Discovery of a novel warhead against beta-secretase through fragment-based lead generation. , 2007, Journal of medicinal chemistry.

[8]  Gianni Chessari,et al.  Application of fragment screening by X-ray crystallography to beta-secretase. , 2007, Journal of medicinal chemistry.

[9]  Gianni Chessari,et al.  From fragment to clinical candidate--a historical perspective. , 2009, Drug discovery today.

[10]  N. Blomberg,et al.  An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes. , 2007, Current topics in medicinal chemistry.

[11]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[12]  Christopher W Murray,et al.  Apo and inhibitor complex structures of BACE (beta-secretase). , 2004, Journal of molecular biology.

[13]  Manuel Buttini,et al.  Partial Reduction of BACE1 Has Dramatic Effects on Alzheimer Plaque and Synaptic Pathology in APP Transgenic Mice* , 2007, Journal of Biological Chemistry.

[14]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[15]  G. Higgins,et al.  Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. , 2004, The Journal of biological chemistry.

[16]  Gianni Chessari,et al.  Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of beta-secretase. , 2007, Journal of medicinal chemistry.

[17]  S. Younkin.  The role of Aβ42 in Alzheimer's disease , 1998, Journal of Physiology-Paris.

[18]  Lingyan Wang,et al.  Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation. , 2010, Journal of medicinal chemistry.

[19]  I. Kola,et al.  BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. , 2001, Human molecular genetics.

[20]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[21]  P. Wong,et al.  The β-Secretase Enzyme BACE in Health and Alzheimer's Disease: Regulation, Cell Biology, Function, and Therapeutic Potential , 2009, The Journal of Neuroscience.

[22]  U. Koch,et al.  From fragment screening to potent binders: strategies for fragment-to-lead evolution. , 2009, Mini reviews in medicinal chemistry.

[23]  C. Abad-Zapatero,et al.  Ligand efficiency indices for effective drug discovery , 2007, Expert opinion on drug discovery.

[24]  Masaya Orita,et al.  Advances in fragment-based drug discovery platforms , 2009, Expert opinion on drug discovery.

[25]  Rajiv Chopra,et al.  Design and synthesis of 5,5'-disubstituted aminohydantoins as potent and selective human beta-secretase (BACE1) inhibitors. , 2010, Journal of medicinal chemistry.

[26]  M. Ohno,et al.  BACE1 Deficiency Rescues Memory Deficits and Cholinergic Dysfunction in a Mouse Model of Alzheimer's Disease , 2004, Neuron.

[27]  W. Richards,et al.  Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation , 2001, Nature Neuroscience.

[28]  S. Bembenek,et al.  Ligand binding efficiency: trends, physical basis, and implications. , 2008, Journal of medicinal chemistry.

[29]  R. Godemann,et al.  Fragment-based discovery of BACE1 inhibitors using functional assays. , 2009, Biochemistry.

[30]  D. E. Clark,et al.  Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. , 1999, Journal of pharmaceutical sciences.

[31]  Xingrong Liu,et al.  Strategies to optimize brain penetration in drug discovery. , 2005, Current opinion in drug discovery & development.

[32]  D. Fattori,et al.  Fragment-Based Approach to Drug Lead Discovery , 2008, Drugs in R&D.

[33]  Y. Kiso,et al.  Recent progress in the drug discovery of non-peptidic BACE1 inhibitors , 2009, Expert opinion on drug discovery.

[34]  S. Younkin.  The role of A beta 42 in Alzheimer's disease. , 1998, Journal of physiology, Paris.

[35]  Daniel F. Wyss and Hugh L. Eaton.  Fragment-Based Approaches to Lead Discovery , 2007 .

[36]  S. Hitchcock,et al.  Structure-brain exposure relationships. , 2006, Journal of medicinal chemistry.

[37]  R. Silvestri.  Boom in the Development of Non‐Peptidic β‐Secretase (BACE1) Inhibitors for the Treatment of Alzheimer′s Disease , 2009 .

[38]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[39]  Matthew S. Johnson,et al.  Aminoimidazoles as potent and selective human beta-secretase (BACE1) inhibitors. , 2009, Journal of medicinal chemistry.

[40]  Walter Huber,et al.  A new strategy for improved secondary screening and lead optimization using high‐resolution SPR characterization of compound–target interactions , 2005, Journal of molecular recognition : JMR.

[41]  Walter Huber,et al.  Biomolecular interaction analysis in drug discovery using surface plasmon resonance technology. , 2006, Current pharmaceutical design.

[42]  Lin Hong,et al.  Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. , 2007, Journal of medicinal chemistry.

[43]  M. Citron,et al.  Alzheimer's disease: strategies for disease modification , 2010, Nature Reviews Drug Discovery.

[44]  Michèle N Schulz,et al.  Recent progress in fragment-based lead discovery. , 2009, Current opinion in pharmacology.

[45]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[46]  Lin Hong,et al.  Subsite Specificity of Memapsin 2 (β-Secretase): Implications for Inhibitor Design† , 2001 .

[47]  I. Hidalgo,et al.  Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. , 2005, International journal of pharmaceutics.

[48]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[49]  Sahil Patel,et al.  Apo and Inhibitor Complex Structures of BACE (β-secretase) , 2004 .

[50]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[51]  Junya Qu,et al.  2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead. , 2007, Journal of medicinal chemistry.

[52]  V. Katta,et al.  Characterization of Alzheimer's beta -secretase protein BACE. A pepsin family member with unusual properties. , 2000 .

[53]  Gianni Chessari,et al.  Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. , 2007, Journal of medicinal chemistry.

[54]  Michael Czarniecki,et al.  Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors. , 2010, Journal of medicinal chemistry.

[55]  Joseph B. Moon,et al.  Design, synthesis, and crystal structure of hydroxyethyl secondary amine-based peptidomimetic inhibitors of human beta-secretase. , 2007, Journal of medicinal chemistry.

[56]  Jay S. Fine,et al.  Chronic Treatment with the γ-Secretase Inhibitor LY-411,575 Inhibits β-Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal Cell Differentiation* , 2004, Journal of Biological Chemistry.